Pay in 4 interest-free payments of $5.62 Learn more
Ships within 48 hours · Estimated delivery Oct 8 - Oct 13
AstraZeneca PLC AstraZeneca is strengthening its portfolio with GLP-1 targeted drugs and actively engaging in clinical trials for obesity-related metabolic conditions
The effects of feed restriction during organogenesis on embryo-fetal development in the rat
Mark Fendrick, who directs the Center for Value-Based Insurance Design at the University of Michigan, has argued that if some people using GLP-1s to lose weight were eventually transitioned off, more people could take advantage of them
FDA labeling and the American Diabetes Association recommend gradual dose titration to minimize gastrointestinal symptoms
Emerging research is investigating whether lower maintenance doses might sustain weight loss while reducing cost and side effect burden, but this approach is not yet supported by randomized controlled trials and should only be undertaken with physician guidance
